Tags

Type your tag names separated by a space and hit enter

Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
Clin Nucl Med. 2016 Nov; 41(11):837-843.CN

Abstract

PURPOSE

To determine whether interim F-FDG PET or interim diffusion-weighted magnetic resonance imaging (DWI) can predict the end-of-treatment (EOT) outcome after immunotherapy in patients with FDG-avid extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT).

MATERIALS AND METHODS

Patients with untreated MALT lymphoma prospectively underwent whole-body F-FDG PET/CT and DWI before treatment (baseline), and after three cycles (interim) of rituximab-based immunotherapy. Maximum and mean standardized uptake values (SUVmax, SUVmean), and minimum and mean apparent diffusion coefficients (ADCmin, ADCmean), were measured for up to three target lesions per patient. Rates of change between baseline and interim examinations (ΔSUVmax, ΔSUVmean, ΔADCmin, and ΔADCmean) were compared, using ANOVAs, between the four end-of-treatment (EOT, after six cycles of immunotherapy) outcomes: complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD).

RESULTS

Fifteen patients with 25 lesions were included. Lesion-based post hoc tests showed significant differences between CR and PR for ΔSUVmax (P < 0.001), ΔSUVmean (P < 0.001), and ΔADCmin (P = 0.044), and between CR and SD for ΔSUVmax (P < 0.001), ΔSUVmean (P < 0.001), ΔADCmin (P = 0.021), and ΔADCmean (P = 0.022). No lesion showed PD at EOT.

CONCLUSIONS

Both quantitative interim F-FDG PET and interim DWI may possibly be useful to predict complete remission at end-of-treatment in MALT lymphoma patients after immunotherapy.

Authors+Show Affiliations

From the *Department of Biomedical Imaging and Image-guided Therapy, †Department of Internal Medicine I, ‡Centre for Medical Physics and Biomedical Engineering, §Institute of Pathology, ∥Department of Internal Medicine III, and #Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27648705

Citation

Mayerhoefer, Marius E., et al. "Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: a Preliminary Study in 15 Patients." Clinical Nuclear Medicine, vol. 41, no. 11, 2016, pp. 837-843.
Mayerhoefer ME, Karanikas G, Kletter K, et al. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients. Clin Nucl Med. 2016;41(11):837-843.
Mayerhoefer, M. E., Karanikas, G., Kletter, K., Kiesewetter, B., Weber, M., Rausch, I., Pones, M., Simonitsch-Klupp, I., Müllauer, L., Dolak, W., Lukas, J., & Raderer, M. (2016). Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients. Clinical Nuclear Medicine, 41(11), 837-843.
Mayerhoefer ME, et al. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: a Preliminary Study in 15 Patients. Clin Nucl Med. 2016;41(11):837-843. PubMed PMID: 27648705.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients. AU - Mayerhoefer,Marius E, AU - Karanikas,Georgios, AU - Kletter,Kurt, AU - Kiesewetter,Barbara, AU - Weber,Michael, AU - Rausch,Ivo, AU - Pones,Matthias, AU - Simonitsch-Klupp,Ingrid, AU - Müllauer,Leonhard, AU - Dolak,Werner, AU - Lukas,Julius, AU - Raderer,Markus, PY - 2016/10/18/pubmed PY - 2017/1/12/medline PY - 2016/9/21/entrez SP - 837 EP - 843 JF - Clinical nuclear medicine JO - Clin Nucl Med VL - 41 IS - 11 N2 - PURPOSE: To determine whether interim F-FDG PET or interim diffusion-weighted magnetic resonance imaging (DWI) can predict the end-of-treatment (EOT) outcome after immunotherapy in patients with FDG-avid extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT). MATERIALS AND METHODS: Patients with untreated MALT lymphoma prospectively underwent whole-body F-FDG PET/CT and DWI before treatment (baseline), and after three cycles (interim) of rituximab-based immunotherapy. Maximum and mean standardized uptake values (SUVmax, SUVmean), and minimum and mean apparent diffusion coefficients (ADCmin, ADCmean), were measured for up to three target lesions per patient. Rates of change between baseline and interim examinations (ΔSUVmax, ΔSUVmean, ΔADCmin, and ΔADCmean) were compared, using ANOVAs, between the four end-of-treatment (EOT, after six cycles of immunotherapy) outcomes: complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD). RESULTS: Fifteen patients with 25 lesions were included. Lesion-based post hoc tests showed significant differences between CR and PR for ΔSUVmax (P < 0.001), ΔSUVmean (P < 0.001), and ΔADCmin (P = 0.044), and between CR and SD for ΔSUVmax (P < 0.001), ΔSUVmean (P < 0.001), ΔADCmin (P = 0.021), and ΔADCmean (P = 0.022). No lesion showed PD at EOT. CONCLUSIONS: Both quantitative interim F-FDG PET and interim DWI may possibly be useful to predict complete remission at end-of-treatment in MALT lymphoma patients after immunotherapy. SN - 1536-0229 UR - https://www.unboundmedicine.com/medline/citation/27648705/Can_Interim_18F_FDG_PET_or_Diffusion_Weighted_MRI_Predict_End_of_Treatment_Outcome_in_FDG_Avid_MALT_Lymphoma_After_Rituximab_Based_Therapy:_A_Preliminary_Study_in_15_Patients_ L2 - https://dx.doi.org/10.1097/RLU.0000000000001395 DB - PRIME DP - Unbound Medicine ER -